Back to top

Analyst Blog

Nektar Therapeutics (NKTR - Analyst Report) announced that most of the members of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) have recommended that no cardiovascular outcomes study is required for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes Movantik (naloxegol oxalate).

Movantik is being developed for the treatment of opioid-induced constipation (OIC) for patients suffering from chronic non-cancer pain. The committee however suggested that post-approval cardiovascular safety data collection for this class of candidates will continue.

The favorable voting comes as a huge relief for Nektar. Additional cardiovascular outcomes studies would have significantly spiked the company’s research and development expenses. We note that Nektar’s stock trading was halted yesterday before the advisory committee meeting. We expect the news to positively impact Nektar’s shares.

Nektar has a worldwide licence agreement with AstraZeneca (AZN - Analyst Report) for Movantik. Movantik is under review in the U.S. for the chronic non-cancer pain indication. A final decision from the FDA on the approval of Movantik is expected by Sep 16, 2014. We note that although the FDA is not bound to follow the advisory committee’s opinion, but it generally does so. Movantik is also under review in the EU and Canada for the same indication.

Nektar also has NKTR-181 in its portfolio being developed for the treatment of chronic pain. The company is in discussion with the FDA regarding the design of a phase III study on NKTR-181 in chronic pain patients.

Nektar has progressed well with its pipeline in the last few quarters and is awaiting several pipeline related events in the coming quarters.

Nektar currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. (GILD - Analyst Report) and Ariad Pharmaceuticals Inc. (ARIA - Snapshot Report). While Gilead carries a Zacks Rank #1 (Strong Buy), Ariad holds a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.55 +11.64%
CHINA BIOLO… CBPO 55.57 +7.40%
LUXOFT HOLD… LXFT 38.77 +3.64%
INSITE VISI… INSV 0.30 +3.41%
BITAUTO HOL… BITA 93.99 +3.21%